The Future of Cell & Gene

While the Cell & Gene industry has experienced rapid advancement recently, it is still in the infant stage and remains financially inaccessible to many patients who require treatment. Advancements in manufacturing processes like standardization are paving the way for more affordable therapy products, helping to make these treatments more accessible.

Maggie Chen, Senior Director, Manufacturing & MSAT, AGC Biologics, shares how partnering with the right CDMO is essential to gain access to innovative manufacturing platforms that reduce cost and accelerate program timelines.